Alliance on Blood Markers for Brain Injury

(Toronto, Canada) in the animal models of Janssen Research Foundation (Beerse, Belgium) for stroke and traumatic brain injury has been announced by the two companies. The effectiveness of the current treatment for stroke depends on immediate medical intervention after onset and is limited to treating only one type of stroke, notes Syn X. With the high incidence of stroke, there is an enormous need for new and more-effective diagnostic and therapeutic drugs.

Syn X capitalizes on its Proteomics Discovery Platform to discover and develop innovative diagnostics and therapeutics for use in preventive medicine and patient management. The company is currently developing several innovative diagnostics for heart failure, hypertension, diabetes, and central nervous system diseases such as Alzheimer's. If the current collaboration proves successful, Janssen will have the option to employ Syn X's Proteomics Discovery Platform to help optimize Janssen's drug development for stroke and Alzheimer's disease.
Janssen Research Foundation, a division of Johnson & Johnson, has conducted extensive research on the central nervous system. The company's research has also focused on analgesia, oncology, and gastroenterology.



Related Links:
Syn X Pharma Inc